In this Lung Cancer Awareness Month video, members of Oncology Data Advisor and MedNews Week join forces to share global perspectives regarding treatment, equity, and patient advocacy in lung cancer.
On the first day of Lung Cancer Awareness Month, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share recent advances in lung cancer research and ways to raise awareness of this disease for both the public and the health care community throughout the month of November. Hear unique perspectives from Matthew Hadfield, DO, Hematology/Oncology Fellow at Brown University; Waqas Haque, MD, MPH, Internal Medicine Resident at New York University; and Samuel Kareff, MD, MPH, Hematology-Oncology Fellow at the University of Miami.
In honor of World Cancer Research Day, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share their passions for cancer research, discuss the recent and upcoming progress in their respective areas of study, and raise awareness for the tireless efforts being undertaken to advance cancer research.
This Fellows Forum episode features Dr. Samuel Kareff and Dr. Matthew Hadfield in a discussion about unique ways to create educational opportunities during Hematology/Oncology Fellowship, including board exam preparation, methods for teaching residents and other fellows, and the value of live and virtual onsite continuing medical education (CME) meetings.
This Oncology Data Advisor® Fellows Forum Interview features Dr. Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, in discussion with Dr. Ana Velazquez Mañana, an Assistant Professor of Medicine in the Division of Hematology-Oncology at the University of California, San Francisco (UCSF), regarding the unique challenges faced by hematology/oncology trainees during the COVID-19 pandemic. Dr. Velazquez Mañana outlines the impacts on clinical training, research, and career development, as well as the positive changes that have been incorporated into the landscape for hematology/oncology trainees.
This Oncology Data Advisor® Fellows Forum Interview features Dr. Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, in discussion with Dr. Ana Velazquez Mañana, an Assistant Professor of Medicine in the Division of Hematology-Oncology at the University of California, San Francisco (UCSF), regarding the unique challenges faced by hematology/oncology trainees during the COVID-19 pandemic. Dr. Velazquez Mañana outlines the impacts on clinical training, research, and career development, as well as the positive changes that have been incorporated into the landscape for hematology/oncology trainees.
Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Samuel Kareff, Chief Hematology/Oncology Fellow at the University of Miami's Sylvester Cancer Center, shares the educational topics that he is looking forward to sharing his insights on as a Fellows Forum member, including tips for fellowship application, specialty pros and cons, research advances, and collaborations with policymakers and patient advocacy groups.
In this interview with Oncology Data Advisor, Dr. Samuel Kareff, a Hematology-Oncology Fellow at Sylvester Comprehensive Cancer Center of the University of Miami, provides a comprehensive overview of the current and emerging therapies used in the treatment of breast cancer, serving as a valuable resource to share with patients who may be discussing these options with their oncology team.
Large population next-generation sequencing of tumors for mutations in certain key oncogenes is an important avenue of research for discovering genes that can predict survival or even support the use of targeted therapies for certain patients. At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Sam Kareff, MD, MPH, presented a poster about his research about how mutations in the oncogene HRAS affect prognosis and response to therapy in breast cancer. He determined that certain types of HRAS mutation are associated with poor survival and that patients with these mutations may benefit from targeted therapies.
This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.